Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to HKD 10.3, for an aggregate consideration of approximately HKD 2.87 million. Following this transaction, the total number of shares stood at 109,096,785, comprising 105,248,985 issued shares (excluding treasury shares) and 3,847,800 treasury shares.

The repurchase falls under a mandate authorized on 11 June 2025, permitting the company to repurchase up to 10,909,678 shares. As of the latest disclosure, 3,847,800 shares have been repurchased under this mandate, representing approximately 3.52696% of the total number of issued shares (excluding treasury shares) on the date the mandate was granted. A moratorium on new share issuance or treasury share sales remains in effect until 12 March 2026.